合作
Regeneron strikes Antibody-Helicon Conjugate collaboration with Parabilis Medicines
Parabilis Medicines announced a strategic collaboration with Regeneron focused on developing Antibody-Helicon Conjugates, under which Parabilis received $125 million — $50 million upfront plus a $75 million equity investment — with potential for up to approximately $2.2 billion in development, regulatory and commercial milestones plus up to low double-digit tiered royalties. Parabilis is not a TradingPilot universe company, so this stays an annotation on Regeneron only.
大盤 開啟原文 ↗